Medical News Today
Real world data presented by Novartis at the 2014 Association for Research in Vision and Ophthalmology (ARVO) Conference this week further support the well-established safety and efficacy profile of Lucentis® (ranibizumab) in wet Age-related Macular Degeneration (AMD).[1] Pivotal clinical trial results also show a flexible dosing approach in patients with Diabetic Macular Oedema (DMO) is non-inferior to a regimen which requires monthly monitoring.[2]